Motavizumab MEDI-524|cas:677010-34-3|西域试剂

Motavizumab MEDI-524,98.35%

产品编号：Bellancom-P99209| CAS NO：677010-34-3

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99209		￥5200.00	杭州北京（现货）
Bellancom-P99209		￥12800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Motavizumab MEDI-524

产品介绍

Motavizumab (MEDI-524) 是一种 anti-human RSV (呼吸道合胞病毒) 单克隆抗体。Motavizumab 可用于高危婴儿的呼吸道合胞病毒感染的研究。

生物活性

Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research.

体外研究

Motavizumab shows activity after F protein initiates interaction with the cell membrane and before virus transcription.
Motavizumab inhibits F protein-mediated cell-to-cell fusion.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Motavizumab (intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once) treatment shows reductions on RSV replication and concentrations of cytokine and chemokines in RSV-infected mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2
Dosage:	1.25 mg in 0.1 ml of PBS/per mouse
Administration:	Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once
Result:	Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5. Showed lower BAL concentrations of IL-1α, IL-12p70, TNF-α and IFN-γ and serum IL-10 and KC compared with RSV-infected untreated mice.

体内研究

Motavizumab (intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once) treatment shows reductions on RSV replication and concentrations of cytokine and chemokines in RSV-infected mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2
Dosage:	1.25 mg in 0.1 ml of PBS/per mouse
Administration:	Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once
Result:	Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5. Showed lower BAL concentrations of IL-1α, IL-12p70, TNF-α and IFN-γ and serum IL-10 and KC compared with RSV-infected untreated mice.